PEDIATRIC ADVIL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PEDIATRIC ADVIL (PEDIATRIC ADVIL).
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
| Metabolism | Primarily hepatic via cytochrome P450 2C9 (CYP2C9) isoenzyme. Metabolites are excreted renally. |
| Excretion | Renal excretion of conjugated metabolites (glucuronides and sulfates) accounts for >90% of an administered dose, with <1% excreted unchanged. Biliary/fecal elimination is minimal (<5%). |
| Half-life | Terminal elimination half-life is approximately 2-4 hours in children. Clinical context: rapid clearance; requires frequent dosing every 6-8 hours for sustained antipyretic/analgesic effect. |
| Protein binding | >99% bound to albumin at therapeutic concentrations. |
| Volume of Distribution | Approximately 0.12-0.2 L/kg in children. Clinical meaning: low Vd indicates limited extravascular distribution consistent with high protein binding. |
| Bioavailability | Oral: 80-100% (rapidly absorbed). |
| Onset of Action | Oral: 15-30 minutes following ingestion; peak effect at 1-2 hours. |
| Duration of Action | Antipyretic/analgesic: 4-8 hours depending on dose. Clinical note: duration is dose-dependent; higher doses extend duration but increase adverse event risk. |
| Molecular Weight | 206.28 |
Ibuprofen 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | GFR 30-59 mL/min: no adjustment; GFR 15-29 mL/min: avoid use; GFR <15 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or avoid; Child-Pugh C: contraindicated. |
| Pediatric use | 6 months to 12 years: 5-10 mg/kg/dose orally every 6-8 hours as needed; maximum 40 mg/kg/day or 1000 mg/day, whichever is less. |
| Geriatric use | Start at lower end of dosing range (200 mg every 6-8 hours); monitor renal function and gastrointestinal tolerance; avoid long-term use if possible. |
| 1st trimester | Avoid unless benefit outweighs risk; associated with miscarriage and cardiac defects. |
| 2nd trimester | Avoid; risk of oligohydramnios and premature closure of ductus arteriosus. |
| 3rd trimester | Contraindicated; risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for PEDIATRIC ADVIL (PEDIATRIC ADVIL).
| Placental transfer | Crosses placenta; achieves fetal concentrations approximately 10% of maternal serum levels. |
| Breastfeeding | Ibuprofen transfers into breast milk in low levels; considered compatible with infant exposure via breastfeeding. However, use lowest effective dose for shortest duration. |
| Lactation Rating |
■ FDA Black Box Warning
NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk.
| Serious Effects |
Known hypersensitivity to ibuprofen or any NSAIDHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or NSAIDsActive or history of recurrent peptic ulcer disease or GI bleedingSevere hepatic impairmentSevere renal impairment (eGFR < 30 mL/min)Third trimester of pregnancyPerioperative pain in setting of coronary artery bypass graft (CABG) surgery
| Precautions | Cardiovascular thrombotic events, including myocardial infarction and stroke, can occur with NSAID use. Risk increases with duration of use and in patients with cardiovascular risk factors., Gastrointestinal events: risk of GI bleeding, ulceration, and perforation., Renal effects: can cause renal papillary necrosis and other renal injury; use with caution in patients with renal impairment or dehydration., Anaphylactoid reactions: may occur in patients with aspirin sensitivity., Hepatic effects: borderline elevations of liver tests may occur; discontinue if signs of hepatic injury develop., Hematological effects: may inhibit platelet aggregation and prolong bleeding time., Fluid retention and edema: use with caution in patients with hypertension or heart failure. |
Loading safety data…
| L1 (Safe) |
| Teratogenic Risk | First trimester: Association with increased risk of miscarriage and congenital malformations (cardiac, gastroschisis). Second trimester: Risk of oligohydramnios and premature closure of ductus arteriosus. Third trimester: Avoid due to risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, and necrotizing enterocolitis. |
| Fetal Monitoring | Maternal: Renal function, blood pressure, gastrointestinal symptoms. Fetal: Ultrasound for oligohydramnios and ductus arteriosus patency if used after 20 weeks gestation. |
| Fertility Effects | Reversible inhibition of ovulation and luteal phase defects due to prostaglandin synthesis inhibition. Effects are transient and resolve upon discontinuation. |
| Food/Dietary | Avoid alcohol consumption. May be taken with food or milk to minimize gastrointestinal irritation. No specific food restrictions, but a balanced diet is recommended. |
| Clinical Pearls | For pediatric patients, weight-based dosing (5-10 mg/kg/dose) is preferred over age-based to avoid under- or overdosing. Use the lowest effective dose for the shortest duration. Avoid in children with dehydration, renal impairment, or varicella due to increased risk of soft tissue infections and renal injury. Contraindicated with recent GI bleeding, peptic ulcer disease, or known NSAID allergies. |
| Patient Advice | Administer with food or milk to reduce stomach upset. · Measure dose using the provided dosing device, not household spoons. · Do not combine with other ibuprofen-containing products or other NSAIDs. · Watch for signs of allergic reaction: rash, facial swelling, difficulty breathing. · Do not use for more than 3 days for fever or 10 days for pain without consulting a doctor. |